Benzodiazepine and Z-Drug Use in Switzerland: Prevalence, Prescription Patterns and Association with Adverse Healthcare Outcomes
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
PURPOSE: This study aimed to give a nationwide comprehensive picture of the prevalence and prescription patterns of benzodiazepines (BZ) and Z-drugs (ZD) in Switzerland and to analyze the association with adverse health care outcomes. PATIENTS AND METHODS: A population-based, cross-sectional study was conducted, using a large health insurance database in Switzerland. Records from all adult patients with ≥1 prescription for a benzodiazepine and/or a Z-drug in 2018 were included. We calculated the prevalence of BZ and ZD user (extrapolated to the Swiss general population), the number of prescriptions and the type of provider (among each BZ and ZD only user). Multivariate logistic regression models were performed to estimate the association between drug prescription and the risk of hospitalization in different healthcare settings. RESULTS: Of a total of 844'692 patients, 95'179 had ≥1 BZ and/or ZD prescription in 2018. The extrapolated one-year prevalence for the general Swiss population was 8.1% for a BZ prescription, 3.5% for a ZD prescription, and 10.5% for a BZ and/or ZD prescription, and continuously increased with age. The majority of the elderly (over 65 years) had ≥1 prescription (BZ: 51.9%; ZD: 56.9%; BZ and/or ZD: 53.5). The proportion of patients with ≥6 prescriptions per year was 23.1% for BZ only user and 35.2% for ZD only user. Most patients had ≥1 prescription from a general practitioner. Regression models showed a higher likelihood to be admitted to acute care, psychiatry, rehabilitation, or nursing home with ≥1 prescription for a benzodiazepine and/or a Z-drug. CONCLUSION: This study is the first to give a nationwide overview of the current use of benzodiazepines and Z-drugs in Switzerland based on health insurance claims data. The results revealed a remarkably high prevalence among the general Swiss population, especially in older generations. The negative consequences of heavy BZ and ZD use are a crucial public health problem, that should be addressed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In 2018, between 8.3% and 12.8% of BZD users in Switzerland have prescriptions from multiple physicians which resulted in the inability to track the number of prescriptions a patient is given yearly [40].”
From Benzodiazepines: Uses, Dangers, and Clinical Considerations (2021) · cites this paper as [40]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15767 · Cited by 3,163
The American Geriatrics Society 2012 Beers Criteria Update Expert Panel (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2012.03923.x · Cited by 2,578
European guideline for the diagnosis and treatment of insomnia
Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., Espie, C. A., Garcia‐Borreguero, D., Gjerstad, M., Gonçalves, M., et al. (2017) · Journal of Sleep Research · doi:10.1111/jsr.12594 · Cited by 2,049 · cited 1×
“9 In the treatment of anxiety disorders, benzodiazepines are important due to their fast onset of action, but are usually a second-line option and used as short-term or additional therapy.”
BackgroundPotentially Inappropriate Medications in the Elderly
Holt, S., Schmiedl, S., & Thürmann, P. A. (2010) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2010.0543 · Cited by 791 · cited 2×
“This finding is of critical importance, especially when considering the classification of benzodiazepines and Z-drugs as potentially inappropriate medication in the elderly on the PRISCUS List (an overview of unsuitable medications in older age groups and recommendations for alternatives), due to an increased risk of…”
BackgroundBenzodiazepine Use in the United States
Olfson, M., King, M., & Schoenbaum, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1763 · Cited by 786
Anxiety disorders in older adults: a comprehensive review
Wolitzky-Taylor, K. B., Castriotta, N., Lenze, E. J., Stanley, M. A., & Craske, M. G. (2010) · Depression and Anxiety · doi:10.1002/da.20653 · Cited by 726 · cited 1×
“The lowering likelihood for psychiatric hospitalization in the elderly can partly be explained by the finding that the prevalence of anxiety disorders declines with older age compared to younger age groups.(65)”
BackgroundBenzodiazepine use and risk of Alzheimer's disease: case-control study
Billioti de Gage, S., Moride, Y., Ducruet, T., Kurth, T., Verdoux, H., Tournier, M., Pariente, A., & Begaud, B. (2014) · BMJ · doi:10.1136/bmj.g5205 · Cited by 558
Increasing Benzodiazepine Prescriptions and Overdose Mortality in the United States, 1996–2013
Bachhuber, M. A., Hennessy, S., Cunningham, C. O., & Starrels, J. L. (2016) · American Journal of Public Health · doi:10.2105/ajph.2016.303061 · Cited by 531
Benzodiazepine use and risk of dementia: prospective population based study
Billioti de Gage, S., Begaud, B., Bazin, F., Verdoux, H., Dartigues, J.-F., Peres, K., Kurth, T., & Pariente, A. (2012) · BMJ · doi:10.1136/bmj.e6231 · Cited by 436
Review of Safety and Efficacy of Sleep Medicines in Older Adults
Schroeck, J. L., Ford, J., Conway, E. L., Kurtzhalts, K. E., Gee, M. E., Vollmer, K. A., & Mergenhagen, K. A. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.09.010 · Cited by 373 · cited 1×
“26,27 Furthermore, hospital patients who were prescribed benzodiazepines during their stay had a higher likelihood to have more bed days in the hospital.”
Background
Research works printed but not linked: 2
- Mihic SJ, Mayfield J, Harris RA. Hypnotics and sedatives. In: Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 13 ed. McGraw-Hill Education; 2017.
- Donato F, Samani F, Marini M, et al. Across-sectional survey on benzodiazepine use among older people in an Italian region. Ital J Public Health. 2005; 2.
Cited by
Benzodiazepines: Uses, Dangers, and Clinical Considerations
Edinoff, A. N., Nix, C. A., Hollier, J., Sagrera, C. E., Delacroix, B. M., Abubakar, T., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2021) · Neurology International · doi:10.3390/neurolint13040059 · Cited by 340
“8% of BZD users in Switzerland have prescriptions from multiple physicians which resulted in the inability to track the number of prescriptions a patient is given yearly [40].”
BackgroundLong-term use of benzodiazepines in chronic insomnia: a European perspective
Soyka, M., Wild, I., Caulet, B., Leontiou, C., Lugoboni, F., & Hajak, G. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1212028 · Cited by 121
“BZDs can be categorized as short-acting [half-life (T1/2) <24 h] and long-acting treatment (T1/2 > 24 h) (72).”
Barbaux, L., Perrault, A. A., Cross, N. E., Weiner, O. M., Essounni, M., Pomares, F. B., Tarelli, L., McCarthy, M., Maltezos, A., Smith, D., et al. (2025) · SLEEP · doi:10.1093/sleep/zsaf168 · Cited by 34
A Need for Benzodiazepine Deprescribing in the COVID-19 Pandemic: A Cohort Study
Bužančić, I., Pejaković, T. I., & Hadžiabdić, M. O. (2022) · Pharmacy · doi:10.3390/pharmacy10050120 · Cited by 16
Representation of Benzodiazepines in Treatment Guidelines: The Paradox of Undesirable Objectivity
Starčević, V. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000524772 · Cited by 12
Sedative drug-use in Denmark, 2000 to 2019: a nationwide drug utilization study
Rosenqvist, T. W., Osler, M., Wium‐Andersen, M. K., & Wium‐Andersen, I. K. (2022) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-022-02409-5 · Cited by 14
“A previous study from Switzerland which characterized users of benzodiazepines and Z-drugs in 2018 showed a three times higher prevalence of multimorbidity compared to non-users [41].”
BackgroundJoye, T., Déglon, J., Donzé, N., Gilardi, F., Sidibé, J., Favrat, B., Augsburger, M. P., & Thomas, A. (2022) · BMC Public Health · doi:10.1186/s12889-022-14883-2 · Cited by 8
McHugh, R. K., Votaw, V. R., McCarthy, M. D., Bichon, J. A., Bailey, A. J., & Fitzmaurice, G. M. (2022) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001115 · Cited by 8
Prescribing Z-drugs in Greece: an analysis of the national prescription database from 2018 to 2021
Siafis, S., Fountoulakis, K. Ν., Fragkidis, V., & Papazisis, G. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04793-x · Cited by 28
Peñarrubia‐María, M. T., Parker, L. A., Puig‐García, M., Fuente‐Moreno, M., Lumbreras, B., López-Pintor, E., Domènech‐Abella, J., Sáez, M., Dima, A. L., Guzmán, A. F., et al. (2025) · Family Medicine and Community Health · doi:10.1136/fmch-2024-003233 · Cited by 8
Almeida‐González, M., Boada, L. D., Putze, G. B., Henríquez‐Hernández, L. A., Luzardo, O. P., Montesdeoca, M. D. P. Q., & Zumbado, M. L. (2022) · Toxics · doi:10.3390/toxics11010045 · Cited by 6
Counselling for Chronic Insomnia in Swiss Pharmacies: A Survey Study Based on Case Vignettes
Mulder, F., Löwinger, D., Jenkinson, S. P., Kaiser, E., Scharf, T., Maire, M., Duss, S. B., Bassetti, C. L., Heinzer, R. C., Auer, R., et al. (2023) · Pharmacy · doi:10.3390/pharmacy11030105 · Cited by 8
“5% for an either/or prescription, and continuously increased with age [19].”
BackgroundÖberg, N. P., Lindström, S. P., Bergqvist, E., Ehnvall, A., Sellin, T., Stefenson, A., Sunnqvist, C., Wærn, M., & Westrin, Å. (2024) · BMC Family Practice · doi:10.1186/s12875-024-02498-y · Cited by 6
“Considering the mean age of the cohort (58 years) it should be pointed out that anxiolytics tend to be common in older populations, both in Sweden [36] and in other countries [37].”
BackgroundBarbaux, L., Cross, N. E., Perrault, A. A., Essounni, M., Desrosiers, C., Clerc, D., Andriamampionona, F., Lussier, D., Tannenbaum, C., Guimond, A., et al. (2025) · Sleep Medicine · doi:10.1016/j.sleep.2025.106826 · Cited by 5
Almeida‐González, M., Boada, L. D., Henríquez‐Hernández, L. A., Luzardo, O. P., Zaragoza, E., Putze, G. B., Montesdeoca, M. D. P. Q., & Zumbado, M. L. (2022) · Toxics · doi:10.3390/toxics10020064 · Cited by 5
“In addition, our results reinforce the data described in Spanish population showing a high rate of consumption of these psychoactive/psychotropic drugs in subjects older than 45 years [46,47].”
ResultGPs’ reflections on prescribing addictive hypnotics to older people: a qualitative study
Skjeie, H., Brekke, M., & Skonnord, T. (2024) · BJGP Open · doi:10.3399/bjgpo.2024.0157 · Cited by 6
Magnusson, D. H., Albertsson, Þ. Í., Jónsdóttir, F., & Sigurdsson, M. I. (2023) · Anaesthesia · doi:10.1111/anae.16041 · Cited by 5
“This mirrors observations from the general population where hypnotic/sedative medication use and long-term treatment are more common among women and the elderly [17, 23].”
BackgroundPrescribing benzodiazepines in young adults with anxiety: a qualitative study of GP perspectives
Archer, C., Wiles, N., Kessler, D. S., Chew-Graham, C. A., & Turner, K. M. (2024) · British Journal of General Practice · doi:10.3399/bjgp.2024.0211 · Cited by 5
Weiss, K., Pichierri, G., Grischott, T., Groth, S., & Neuner‐Jehle, S. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-075828 · Cited by 3
Osler, M., Rosenqvist, T. W., Wium‐Andersen, I. K., Wium‐Andersen, M. K., Sloth, M. M. B., Larsen, E. N., Jørgensen, M. B., & Gronemann, F. H. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.12.040 · Cited by 2
Vogel, M., & Caflisch, C. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21074-7.00017-4 · Cited by 2
Bögli, S. Y., Capone, C., Baumgartner, M. R., Quednow, B. B., Kræmer, T., Keller, E., & Binz, T. M. (2024) · Neurocritical Care · doi:10.1007/s12028-024-02052-9 · Cited by 1
“On average, close to 9% of the Swiss population receives at least one prescription per year (more than 20% of the population aged 65 and above) [29].”
Anders, R., Chapoutot, M., Meloni, F., Peter‐Derex, L., Gustin, M., & Putois, B. (2024) · Journal of Behavioral and Cognitive Therapy · doi:10.1016/j.jbct.2024.100510 · Cited by 1
Lütolf, M., Bregenzer, A., Bruggmann, P., Moriggia, A., Scheidegger, C., Hensel-Koch, K., Batänjer, E. C., Thurnheer, M. C., Santa, P. D., Senn, O., et al. (2025) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2025.100404 · Cited by 1
“Particularly noteworthy is the higher prevalence of psychotropic medication prescriptions, specifically antidepressants (38.1 % versus an estimated 9.0 % (Amrein et al., 2023)), benzodiazepines and Z-drugs (30.3 % versus 10.5 % (Landolt et al., 2021)), and antipsychotics (27.8 % in the cohort).”
InfluentialRomaszko, M. Z., Glińska-Lewczuk, K., Kocbach-Przudzik, A., & Majewski, M. S. (2026) · Chronobiology International · doi:10.1080/07420528.2026.2682479 · Cited by 1
“The available literature offers reports confirming that women are more likely to use hypnotics, sedatives, and antidepressants (Landolt et al. 2021; McHugh et al. 2021; Sanchez-Ruiz et al. 2023).”
Westhoff, M. S., Toto, S., Bleich, S., Grohmann, R., & Seifert, J. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122322 · Cited by 1
Recommandations pour la prévention, le diagnostic et la thérapie des addictions à l’âge avancé
Popp, J., Fuchs, A., Hemmeter, U., Ibach, P. B., Indermaur, E., Klöppel, S., Laimbacher, S., Latanioti, M., Leyhe, T., Lötscher, C., et al. (2022) · JMIG · doi:10.53738/revmed.2022.18.797.1817 · Cited by 1
Frequência de uso de benzodiazepínicos na atenção primária: uma revisão sistemática
Farias, F. T. G., Lima, J. E. M., Pecoraro, L. M., Brito, F. G. D. B., Sousa, L. H. C. C., Paulo, M. M. D. S. F., Almeida, E. P. D. O., & de Sousa, M. N. A. (2022) · Revista Brasileira de Educação e Saúde · doi:10.18378/rebes.v12i1.9366
Siafis, S., Fountoulakis, K. Ν., Fragkidis, V., & Papazisis, G. (2023) · Figshare · doi:10.6084/m9.figshare.23240044
Joye, T., Déglon, J., Donzé, N., Gilardi, F., Sidibé, J., Favrat, B., Augsburger, M., & Thomas, A. (2023) · Figshare · doi:10.6084/m9.figshare.22608025
Joye, T., Déglon, J., Donzé, N., Gilardi, F., Sidibé, J., Favrat, B., Augsburger, M., & Thomas, A. (2022) · Figshare · doi:10.6084/m9.figshare.22608034
Thomas, A. U. (2021) · ScholarWorks (Walden University)
MisuMedPT : use and misuse of psychoactive medicines in Portugal
Carmona Araújo, A. (2024) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Prescription patterns of benzodiazepines and Z-drugs in Berlin prisons
Schwarzer, N., Krebs, J., Konrad, N., Lehmann, M., & Welke, J. (2026) · International Journal of Law and Psychiatry · doi:10.1016/j.ijlp.2026.102189
Pathways to chronic benzodiazepine use: a qualitative study of user and professional perspectives
Peñarrubia‐María, M. T., Olmos-Palenzuela, M. D. C., Gil‐Girbau, M., Rubio-Valera, M., Puig‐García, M., Guilabert, M., López-Pintor, E., Chilet‐Rosell, E., Parker, L. A., & Aznar-Lou, I. (2026) · BMC Family Practice · doi:10.1186/s12875-026-03250-4
“Internationally, in general population, there is great variability in use prevalence (including chronic and non-chronic use) across different countries, ranging from 2% to 18% [5–7].”
Wang, F., Meng, L., Bogar, K. F., Brensinger, C. M., Bilker, W. B., Dublin, S., Hecht, T. E. H., Horn, J. R., Moga, D. C., Thase, M. E., et al. (2026) · Clinical Drug Investigation · doi:10.1007/s40261-026-01582-8
“Benzodiazepine use is consistently high among many Western European nations, although the prevalence differs by country [3–5].”
Metadata
- Authors
- Landolt, S., Rosemann, T., Blozik, E., Brüngger, B., & Huber, C. A.
- Affiliations
- University of Zurich (CH)
- Helsana Group (Switzerland) (CH)
- Corresponding author
- Huber, Carola A
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2021-04
- Volume
- Volume 17
- Pages
- 1021-1034
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- PMC
- PMC8052118
- OpenAlex
- W3154783048
- Cited by
- 34
- References
- 58
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 8 · 2023: 6 · 2022: 10 · 2021: 1
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- benzodiazepines, Z-drugs, prescribing patterns, prevalence, hospitalization, older adults, general practitioners, health insurance claims data, Switzerland
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.